246 results about "Myocardial ischaemia" patented technology

Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.

A method for the diagnosis of acute myocardial, ischaemic diseases, for example acute myocardial infarct, particularly without increasing ST-paths in EKG (NSTEMI). At least two markers on a patient, who is to examined, are determined. A kit for carrying out said diagnostic method, including a test strip for carrying out quick tests.

Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.

The invention relates to a fingerprint map for controlling the quality and efficacy of rhizoma corydalis and preparation of the rhizoma corydalis and a preparation method of the fingerprint map. The invention discloses that the fingerprint map is one of anti-myocardial ischemic active site in the rhizoma corydalis, and the active site mainly comprises quaternary ammonium base components, wherein, columbamine, 13-methyldehydrocorydalmine, dehydrocorybulbine, palmatine, dehydrocorydaline are the main five components of quaternary ammonium base. The fingerprint map can identify the authenticity of samples and evaluate the quality and efficacy of the rhizoma corydalis or the preparation thereof, so that the quality of the rhizoma corydalis and the preparation thereof have real controllable standards, so as to ensure the product quality to be stable. The method has the advantages of being simple to operate and being accurate and reliable, which is applicable to controlling the quality and efficacy of the rhizoma corydalis and the preparation thereof.

The invention relates to a novel 5, 6, 7- tri-oxygen Dihydroflavonol, shown in formula (1), the preparation method and its application. The compound can be used to prepare drug combination that can prevent hepatitis b, protect liver, treat fungal infection, prevent diseases that generates free radical during disease change including inflammation, autoimmune diseases, radiotherapy sequela, tumor, myocardial ischemia, cardiac hypertrophy, aging, allergic reaction and atherosclerosis. There are various preparations for said drug combination.

Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.

There is provided a system, method and apparatus for detecting a cardiac event in a subject, including: at least one electrode attached to the subject for obtaining an electrocardiogram of the subject's heart; and means for determining a size of an area under a QRS complex of the electrocardiogram. The at least one electrode may be attached to the subject's skin or to the subject's heart. Preferably, the means for determining the size of the area under the QRS complex of the electrocardiogram is either visual or quantitative. The subject may be a human being or an animal. It is advantageous that the size of the area under the QRS complex of the electrocardiogram is directly proportional to the mass of viable myocardium in the subject's heart. The cardiac event that may be detected may be degenerative cardiomyopathy, acute myocardial infarction, arrhythmia, myocardial ischaemia, or compromised ventricular function.

The present invention relates to a medicine adopting succinyl ononin represented by a formula (1) and a pharmaceutically acceptable salt as an active component, and applications of the medicine in preparation of a cardiovascular disease medicine, particularly to applications of succinyl ononin and a pharmaceutically acceptable salt in preparation of an anti-myocardial ischemia drug, and belongs to the technical field of medicines. According to the present invention, the provided succinyl ononin is the new ononin derivative, has high water solubility and low toxicity, provides significant treatment effects for cardiovascular diseases, especially myocardial ischemic diseases, and provides the new drug selection for cardiovascular diseases. The formula (1) is defined in the specification.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

The present invention provides an extracting process of poria, cinnamom, largehead atractylodes and licorice decoction and the process is optimized through orthogonal design. In the recipe, the ratioof poria, cinnamom, largehead atractylodes and licorice is 12 to 9 to 9 to 6, and the medicine materials are solvent extracted. The selected solvent includes water and ethyl alcohol solution in different concentration and the extraction process may be either one including first water extraction and ethyl alcohol precipitation or one including first ethyl alcohol extraction and water precipitation. The present invention may be used in preparing medicine for treating myocardial ischemia and arrhythmia.

Disclosed are A3 adenosine receptor antagonists and / or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The antagonists or partial agonists find use in treating a number of diseases including cancer, glaucoma, inflammatory diseases, asthma, stroke, myocardial infarction, allergic reactions, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, brain arteriole diameter constriction, bronchoconstriction, and myocardial ischemia, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs.

The invention belongs to the technical field of traditional Chinese medicines and in particular relates to a traditional Chinese medicine preparation for adjusting hypertension, hyperlipemia and hyperglycemia. The traditional Chinese medicine preparation is prepared from the following components in parts by weight: 8-20 parts of apium graveolens, 8-20 parts of roots of red-rooted salvia, 5-15 parts of sanchi flowers, 10-30 parts of red rhodobryum, 10-30 parts of roots of kudzu vines, 5-15 parts of anoectochilus formosanus, 5-15 parts of radix cynanchi bungei, 5-15 parts of dendrobe and 20-30 parts of sweet potato leaves. The traditional Chinese medicine preparation is obtained by combining the multi-year clinical experience summary of the investor through repeated experiments on the basis of the secret prescription handed down from ancestors, so that the preparation has a special curative effect on the refractory hypertension, hyperlipemia and hyperglycemia. By scientifically combining the plurality of drugs and compressively applying the preparation, the active ingredients of the drug can quickly enter blood circulation, so that blood cholesterol is lowered, thrombogenesis is blocked, coronary artery is expanded, blood flow volume is increased, myocardial ischemia tolerance is improved, cerebral infarction is improved and damaged cranial nerves are recovered, and therefore, patients with hypertension, hyperlipemia and hyperglycemia are quickly recovered. The traditional Chinese medicine preparation disclosed by the invention has the special curative effect to hypertension, hyperlipemia, diabetes mellitus, brain atrophy, cerebral thrombosis, coronary heart disease, cerebral arteriosclerosis and sequela of apoplexy. Moreover, the traditional Chinese medicine preparation is quick to become effective, short in treatment course, high in cure rate and small in expense.

Furanone derivatives and the pharmaceutically acceptable salts thereof have cytoprotective activity and protective activity for neuroinflammation, and neurodegenerative disorders; they are useful in the treatment of stroke, cerebral ischemia, myocardial infarction, myocardial ischemia, chronic heart failure, inflammation and other oxidative stress-related conditions, as well as Alzheimer's disease and senile dementia; they are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.

The invention provides homoisoflavonoid compounds, which are prepared by the following steps: grinding dwarf lilyturf tuber, adding extraction solvent into the ground dwarf lilyturf tuber according to a weight / volume ratio of the medicinal material to the solvent of 1:(6-10), performing normal-temperature extraction or reflux extraction, mixing extract solution, concentrating under reduced pressure, dissolving the extract in water, extracting in an organic solvent, recovering solvent to obtain coarse total homoisoflavonoid, loading onto a macroporous resin for eluting to obtain total homoisoflavonoid active part extract, and obtaining the homoisoflavonoid compounds by separation by normal silica gel, reversed silica gel and aluminum oxide column chromatography. A cell level H9C2 cardiac muscle cell line oxygen-glucose deprivation pharmacological model proves that the homoisoflavonoid compounds have anti-myocardial ischemia activity and can be used for preparing medicines for treating cardiovascular diseases such as ischemic heart diseases, coronary diseases, myocardial ischemia, myocardial infarction, stenocardia, arrhythmia and cardiac insufficiency. The general structural formula of the compound is shown below.

The invention relates to a pseudoginsenoside G1 and an extraction method and medicinal applications thereof, belonging to a new compound and medicinal applications thereof. The method comprises the following steps: taking Red American ginseng to grind, adding 3-7 times of 70-95% ethanol to heat and reflux for extraction, wherein each extraction requires 2-4 hours and 3-6 times of extractions are needed; mixing the extracting solutions, recovering the solvent till dry; adopting the silica gel column chromatography to treat ethanol extract, wherein the eluent is CHCl3-MeOH and the weight ratio is 80-110:20-40; adopting the C-18 reversed phase column chromatography to treat, wherein the eluent is MeOH-H2O and the weight ratio is 50-70:30-50; and using the mixture of methanol and water in a weight ratio of 1:2-5 to perform crystallization and obtain the pseudoginsenoside G1. The chemical name of the product is 3-O-[beta-D-glucopyranosyl-(1-2)-beta-D-glucopyranosyl]-dammarane-12-one-20S,24R-epoxy-3beta,25-diol. The pseudoginsenoside G1 can be used in the preparation of medicines for curing myocardial infarction, resisting myocardial ischemia and reducing the adhesion and aggregation of platelets.

Disclosed is a system for the detection of cardiac events that includes an implanted device called a cardiosaver, a physician's programmer and an external alarm system. The system is designed to provide early detection of cardiac events such as acute myocardial infarction or exercise induced myocardial ischemia caused by an increased heart rate or exertion. The system can also alert the patient with a less urgent alarm if a heart arrhythmia is detected. Using different algorithms, the cardiosaver can detect a change in the patient's electrogram that is indicative of a cardiac event within five minutes after it occurs and then automatically warn the patient that the event is occurring. To provide this warning, the system includes an internal alarm sub-system (internal alarm means) within the cardiosaver and / or an external alarm system (external alarm means) which are activated after the ST segment of the electrogram exceeds a preset threshold.